These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31345838)

  • 1. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
    Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
    Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
    Lin TA; McCaw ZR; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Sherry AD; Noticewala SS; Fuller CD; Thomas CR; Sun R; Lee JJ; Lin R; Yuan Y; Shyr Y; Meirson T; Ludmir EB
    Clin Cancer Res; 2024 Oct; 30(20):4791-4799. PubMed ID: 39133081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.
    Xu Z; Park Y; Liu K; Zhu B
    J Hematol Oncol; 2020 Mar; 13(1):20. PubMed ID: 32171307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing therapeutic cancer vaccine trials with delayed treatment effect.
    Xu Z; Zhen B; Park Y; Zhu B
    Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust group sequential designs for trials with survival endpoints and delayed response.
    Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
    Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design for immuno-oncology clinical trials enrolling both responders and nonresponders.
    Xu Z; Zhu B; Park Y
    Stat Med; 2020 Nov; 39(27):3914-3936. PubMed ID: 32944979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined test versus logrank/Cox test in 50 randomised trials.
    Royston P; Choodari-Oskooei B; Parmar MKB; Rogers JK
    Trials; 2019 Mar; 20(1):172. PubMed ID: 30885277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials.
    Péron J; Roy P; Ozenne B; Roche L; Buyse M
    JAMA Oncol; 2016 Jul; 2(7):901-5. PubMed ID: 27124210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.
    Sherry AD; Msaouel P; Kouzy R; Abi Jaoude J; Lin TA; Taniguchi CM; Fuller CD; Minsky B; Ludmir EB
    Oncologist; 2024 Jul; 29(7):547-550. PubMed ID: 38824414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes.
    Yang S; Ambrosius WT; Fine LJ; Bress AP; Cushman WC; Raj DS; Rehman S; Tamariz L
    Clin Trials; 2018 Jun; 15(3):305-312. PubMed ID: 29671345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical Studies.
    Gao X; Zhang L; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2262-2267. PubMed ID: 29279318
    [No Abstract]   [Full Text] [Related]  

  • 16. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings.
    Castañon E; Sanchez-Arraez A; Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A
    Eur J Cancer; 2020 Sep; 136():159-168. PubMed ID: 32698098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimality of testing procedures for survival data in the nonproportional hazards setting.
    Arfè A; Alexander B; Trippa L
    Biometrics; 2021 Jun; 77(2):587-598. PubMed ID: 32535892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved endpoints for cancer immunotherapy trials.
    Hoos A; Eggermont AM; Janetzki S; Hodi FS; Ibrahim R; Anderson A; Humphrey R; Blumenstein B; Old L; Wolchok J
    J Natl Cancer Inst; 2010 Sep; 102(18):1388-97. PubMed ID: 20826737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
    Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
    JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.